Innovative new treatment option for patients with uncontrolled hypertension now available in the United States   PALO ALTO, Calif. — Nov. 10, 2023 — Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices

Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S. Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka

Analysis shows a maintained blood pressure lowering effect with fewer added medications following treatment with the Paradise Ultrasound Renal Denervation system   Palo Alto, Calif. – October 26, 2023 – Recor Medical, Inc. (“Recor”) and its parent company,

Presentations include late-breaking results of six-month pooled analysis of data from the RADIANCE™ Global Clinical Trial Program   Palo Alto, Calif. – October 20, 2023 – Recor Medical, Inc. (“Recor”), a subsidiary of Otsuka Medical Devices Co.,

The new guidelines are designed to serve as a resource on the latest scientific evidence for healthcare professionals around the world who treat people with hypertension.

Study results showed that the Paradise Ultrasound Renal Denervation (uRDN) System successfully reduced blood pressure compared to sham.

Ms. Barghout brings more than 20 years of experience leading global businesses in the medical device industry.

The Paradise uRDN System is designed to reduce sympathetic nerve activity by denervating nerves which surround the renal arteries with the goal of reducing blood pressure.

The results come from analysis of the pooled data from ReCor’s RADIANCE Global Clinical Trial Program.